Defibrotide Sodium Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 200 mg

Reference Brands: Defitelio (USA/EU)

Category: Critical Care

Defibrotide Sodium is available in Injection and strengths such as 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Defibrotide Sodium is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Defibrotide Sodium can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Defibrotide sodium is a polydeoxyribonucleotide-based therapeutic agent with antithrombotic, thrombolytic, and fibrinolytic properties. It is composed of a mixture of single-stranded oligonucleotides purified from porcine intestinal mucosa and formulated as a sodium salt for intravenous administration. Defibrotide sodium is marketed under the brand name Defitelio and is primarily used in the management of hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome, in patients who have undergone hematopoietic stem cell or bone marrow transplantation.

Defibrotide sodium exerts its activity by protecting the endothelial cells that line blood vessels, particularly within the liver. It promotes the release of prostacyclin (prostaglandin I₂) and reduces the expression of adhesion molecules on endothelial cells. These actions interfere with platelet and leukocyte adhesion to the vascular endothelium, helping to restore endothelial function and maintain microvascular blood flow. Unlike conventional anticoagulants, defibrotide sodium supports fibrinolysis and endothelial stability without causing significant systemic anticoagulation.

Although the precise mechanism of action is not fully understood, defibrotide sodium plays a supportive role in reducing vascular injury and thrombotic complications associated with veno-occlusive disease following transplantation.